Lilly (LLY) Phase III Study in Ulcerative Colitis Meets Goal Posted byZacks Equity Research December 15, 2021 Leave a comment on Lilly (LLY) Phase III Study in Ulcerative Colitis Meets Goal Eli Lilly’s (LLY) mirikizumab meets primary and key secondary endpoints in a phase III maintenance study in ulcerative colitis.